Ellen Budiono
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ellen Budiono has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Kae Won Cho
Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan, Korea
3 shared publications - Maria Averia
Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan, Korea
3 shared publications - Shindy Soedono
Soonchunhyang Institute of Medi-Bio Science (SIMS), Soonchunhyang University, Cheonan, Korea
3 shared publications - Vivi Julietta
Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan, Korea
3 shared publications - Esther Jin Joo
Department of Integrated Biomedical Science, Soonchunhyang University, Cheonan, Korea
2 shared publications - Hyeong Kyu Park
Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea
2 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 41 (5) , 623-637
Persistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide
Background: Obesity is characterized by chronic inflammation and fibrosis of adipose tissue; however, the extent to which these pathological features persist during pharmacologically induced weight loss remains poorly understood. This study investigated the effects of tirzepatide, a dual agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, on adipose tissue inflammation and fibrosis in obese mice.Methods: Diet-induced obesity was treated with tirzepatide or vehicle for 25 days. Metabolic parameters, tissue inflammation, fibrosis, and macrophage activation were assessed using histology, flow cytometry, gene expression analyses, and immunoblotting. In vitro experiments were conducted to compare the effects of tirzepatide on classically activated and metabolically activated macrophages.Results: Tirzepatide significantly reduced body weight and adiposity, increased energy expenditure, and upregulated thermogenic and mitochondrial proteins in brown adipose tissue. Hyperglycemia and glucose intolerance were normalized. However, adipose tissue inflammation and fibrosis persisted despite weight loss, as evidenced by sustained immune cell infiltration, collagen deposition, and activation of Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling. In contrast, hepatic inflammation and fibrosis were substantially improved. Mechanistically, tirzepatide suppressed inflammatory gene expression in classically activated macrophages but not in metabolically activated macrophages, suggesting that the local metabolic context determines tissue responsiveness to its anti-inflammatory actions.Conclusion: Tirzepatide exerts distinct tissue-specific effects on inflammation and fibrosis during weight loss, ameliorating hepatic pathology while sparing adipose tissue inflammation. These findings identify metabolically activated macrophages as potential determinants of tissue-specific inflammatory persistence and underscore the need for therapeutic strategies that target macrophage activation and fibrotic remodeling to achieve durable metabolic benefits during pharmacological weight loss.
- 31 October 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
- Vol. 41 (5) , 623-637
Open AccessPersistent Adipose Inflammation Despite Metabolic Recovery Reveals Tissue-Specific Immunomodulation by Tirzepatide
Background: Obesity is characterized by chronic inflammation and fibrosis of adipose tissue; however, the extent to which these pathological features persist during pharmacologically induced weight loss remains poorly understood. This study investigated the effects of tirzepatide, a dual agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, on adipose tissue inflammation and fibrosis in obese mice.Methods: Diet-induced obesity was treated with tirzepatide or vehicle for 25 days. Metabolic parameters, tissue inflammation, fibrosis, and macrophage activation were assessed using histology, flow cytometry, gene expression analyses, and immunoblotting. In vitro experiments were conducted to compare the effects of tirzepatide on classically activated and metabolically activated macrophages.Results: Tirzepatide significantly reduced body weight and adiposity, increased energy expenditure, and upregulated thermogenic and mitochondrial proteins in brown adipose tissue. Hyperglycemia and glucose intolerance were normalized. However, adipose tissue inflammation and fibrosis persisted despite weight loss, as evidenced by sustained immune cell infiltration, collagen deposition, and activation of Yes-associated protein (YAP)/transcriptional coactivator with PDZ-binding motif (TAZ) signaling. In contrast, hepatic inflammation and fibrosis were substantially improved. Mechanistically, tirzepatide suppressed inflammatory gene expression in classically activated macrophages but not in metabolically activated macrophages, suggesting that the local metabolic context determines tissue responsiveness to its anti-inflammatory actions.Conclusion: Tirzepatide exerts distinct tissue-specific effects on inflammation and fibrosis during weight loss, ameliorating hepatic pathology while sparing adipose tissue inflammation. These findings identify metabolically activated macrophages as potential determinants of tissue-specific inflammatory persistence and underscore the need for therapeutic strategies that target macrophage activation and fibrotic remodeling to achieve durable metabolic benefits during pharmacological weight loss.
- 22 October 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
Transient Adipose Inflammatory Remodeling during High-Dose Semaglutide-Induced Weight Loss and Regain
Weight loss improves obesity-associated metabolic dysfunction, yet resolution of adipose inflammation may be incomplete and can reappear during weight regain. Whether high-dose semaglutide induces sustained immunological remodeling of adipose and hepatic tissues during weight cycling remains unclear. Male C57BL/6 mice with diet-induced obesity were treated with semaglutide (60 nmol/kg, intraperitoneally, every 3 days) or vehicle for 3 weeks, followed by drug withdrawal under continued high-fat diet feeding. Body weight, body composition, and glucose homeostasis were assessed during treatment and after weight regain. Inflammatory changes in visceral and subcutaneous adipose tissue and liver were analyzed by flow cytometry, histology, immunofluorescence, and gene expression profiling. Semaglutide induced rapid fat mass-selective weight loss with preservation of lean mass and significantly improved fasting glucose, insulin levels, insulin sensitivity, and glucose tolerance. During treatment, visceral adipose tissue exhibited marked reductions in pro-inflammatory macrophages, crown-like structures, and inflammatory gene expression, whereas subcutaneous adipose tissue was minimally affected. Following withdrawal, mice rapidly regained weight and adiposity. Visceral adipose inflammation fully reverted, with macrophage infiltration and inflammatory gene expression comparable to chronically obese controls. Hepatic steatosis and inflammatory markers similarly returned to obese levels. Despite this tissue-level reversion, fasting glycemia and insulin levels remained partially improved. High-dose semaglutide induces robust metabolic improvement and transient suppression of visceral adipose inflammation during active treatment; however, these inflammatory changes are not sustained after withdrawal and largely revert with weight regain. In contrast, partial improvement in fasting glycemia persisted, suggesting differential durability between systemic metabolic adaptation and local inflammatory remodeling during pharmacological weight cycling.
- 22 October 2026
- Published by Korean Endocrine Society in Endocrinology and Metabolism
Transient Adipose Inflammatory Remodeling during High-Dose Semaglutide-Induced Weight Loss and Regain
Weight loss improves obesity-associated metabolic dysfunction, yet resolution of adipose inflammation may be incomplete and can reappear during weight regain. Whether high-dose semaglutide induces sustained immunological remodeling of adipose and hepatic tissues during weight cycling remains unclear. Male C57BL/6 mice with diet-induced obesity were treated with semaglutide (60 nmol/kg, intraperitoneally, every 3 days) or vehicle for 3 weeks, followed by drug withdrawal under continued high-fat diet feeding. Body weight, body composition, and glucose homeostasis were assessed during treatment and after weight regain. Inflammatory changes in visceral and subcutaneous adipose tissue and liver were analyzed by flow cytometry, histology, immunofluorescence, and gene expression profiling. Semaglutide induced rapid fat mass-selective weight loss with preservation of lean mass and significantly improved fasting glucose, insulin levels, insulin sensitivity, and glucose tolerance. During treatment, visceral adipose tissue exhibited marked reductions in pro-inflammatory macrophages, crown-like structures, and inflammatory gene expression, whereas subcutaneous adipose tissue was minimally affected. Following withdrawal, mice rapidly regained weight and adiposity. Visceral adipose inflammation fully reverted, with macrophage infiltration and inflammatory gene expression comparable to chronically obese controls. Hepatic steatosis and inflammatory markers similarly returned to obese levels. Despite this tissue-level reversion, fasting glycemia and insulin levels remained partially improved. High-dose semaglutide induces robust metabolic improvement and transient suppression of visceral adipose inflammation during active treatment; however, these inflammatory changes are not sustained after withdrawal and largely revert with weight regain. In contrast, partial improvement in fasting glycemia persisted, suggesting differential durability between systemic metabolic adaptation and local inflammatory remodeling during pharmacological weight cycling.
- Open Access
- 1 January 2026
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 6 (2) , 270
Dendritic Cell-Specific DPP4 Deficiency Attenuates Obesity-Induced Adipose Tissue Inflammation and Glucose Intolerance
Soedono S, et al. Cardiometab Syndr J. 2026 ;6:e20. https://doi.org/10.51789/cmsj.2026.6.e20
- 1 January 2026
- Published by XMLink in CardioMetabolic Syndrome Journal
- Vol. 6 (2) , 270
Open AccessDendritic Cell-Specific DPP4 Deficiency Attenuates Obesity-Induced Adipose Tissue Inflammation and Glucose Intolerance
Soedono S, et al. Cardiometab Syndr J. 2026 ;6:e20. https://doi.org/10.51789/cmsj.2026.6.e20